| 67.84 -2.52 (-3.58%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 81.67 |
1-year : | 88.84 |
| Resists | First : | 69.93 |
Second : | 76.06 |
| Pivot price | 71.33 |
|||
| Supports | First : | 60 |
Second : | 49.92 |
| MAs | MA(5) : | 70.09 |
MA(20) : | 70.49  |
| MA(100) : | 58.85 |
MA(250) : | 67.28 |
|
| MACD | MACD : | 1.5 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 41.7 |
D(3) : | 50.5 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 118.83 | Low : | 29.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GRAL ] has closed above bottom band by 9.5%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 72.19 - 72.78 | 72.78 - 73.17 |
| Low: | 66.3 - 66.92 | 66.92 - 67.34 |
| Close: | 67.03 - 67.99 | 67.99 - 68.63 |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Sat, 25 Jul 2026
GRAL 10-DAY DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) - GlobeNewswire
Sat, 25 Jul 2026
Investors in GRAIL, Inc. (GRAL): Protect Your Rights - Contact Levi & Korsinsky Before August 4, 2026 - ACCESS Newswire
Fri, 24 Jul 2026
GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm - WBOC TV
Thu, 23 Jul 2026
How Grail Inc Com (GRAL) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 23 Jul 2026
GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - The National Law Review
Thu, 23 Jul 2026
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 83.5 (%) |
| Shares Short | 7,750 (K) |
| Shares Short P.Month | 6,360 (K) |
| EPS | -9.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 60.79 |
| Profit Margin | -253.3 % |
| Operating Margin | -332.9 % |
| Return on Assets (ttm) | -11.5 % |
| Return on Equity (ttm) | -16.1 % |
| Qtrly Rev. Growth | 28.1 % |
| Gross Profit (p.s.) | 1.79 |
| Sales Per Share | 3.63 |
| EBITDA (p.s.) | -8.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -291 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -6.94 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 18.65 |
| Price to Cash Flow | -10.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|